Myriad Genetics Expects to Reach Resolution With UnitedHealthcare Over Pharmacogenetic Testing Before Yearend

MT Newswires Live2024-12-11

Myriad Genetics (MYGN) said late Tuesday that it seeks to reach a resolution with UnitedHealth Group's (UNH) UnitedHealthcare on medical policy for pharmacogenetic tests, including Myriad's GeneSight test, before the yearend, but discussions may continue into early next year.

"We remain steadfast in our confidence in the clinical validity and utility of GeneSight, which we believe is supported by clinical evidence, including peer-reviewed research studies," Myriad quoted its chief executive officer, Paul Diaz, as saying in a statement.

Last month, UnitedHealthcare published its updated medical policy limiting coverage access to multi-gene panel pharmacogenetic tests, including the GeneSight test, under the commercial and individual exchange benefit plans beginning Jan. 1.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment